Compare FKWL & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | VERU |
|---|---|---|
| Founded | 1981 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.7M | 40.9M |
| IPO Year | 1997 | 1996 |
| Metric | FKWL | VERU |
|---|---|---|
| Price | $3.74 | $2.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $22.50 |
| AVG Volume (30 Days) | 6.0K | ★ 51.7K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 94.12 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $46,086,901.00 | $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | $37.30 | ★ N/A |
| Revenue Growth | ★ 49.65 | N/A |
| 52 Week Low | $3.52 | $0.36 |
| 52 Week High | $5.48 | $4.59 |
| Indicator | FKWL | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 44.64 |
| Support Level | $3.73 | $2.13 |
| Resistance Level | $3.94 | $2.70 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 77.27 | 25.93 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.